Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | GLA | P06280 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31668718 | 0.78 | ADRA2A (0.45) | ALDH1A1GLAKDM4EGAAHPGD | |
| SCHEMBL8030619 | 0.78 | ADRA2A (0.45) | ALDH1A1GLAKDM4EGAAHPGD | |
| SCHEMBL21509553 | 0.77 | TRPC5 (0.35) | ALDH1A1GLAKDM4EGAAHPGD | |
| SCHEMBL20987528 | 0.76 | ALDH1A1 (0.36) | ALDH1A1GLAKDM4EGAAHPGD | |
| SCHEMBL21855816 | 0.76 | PSMD14 (0.42) | ALDH1A1GLAKDM4EGAAHPGD | |
| SCHEMBL25072709 | 0.76 | ALDH1A1 (0.36) | ALDH1A1GLAKDM4EGAAHPGD | |
| SCHEMBL19152608 | 0.76 | PRMT5 (0.49) | NOS1ALDH1A1GLAKDM4EGAA | |
| SCHEMBL3364159 | 0.76 | ADORA3 (0.38) | ALDH1A1GLAKDM4EGAAHPGD | |
| SCHEMBL30081465 | 0.76 | CYP11B1 (0.44) | ALDH1A1GLAKDM4EGAAHPGD | |
| SCHEMBL30007438 | 0.76 | ADORA3 (0.38) | ALDH1A1GLAKDM4EGAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025235363-A1 | CYCLIN-DEPENDENT KINASE 4 DEGRADERS | BLUEPRINT MEDICINES CORPORATION (US) | 2025-11-13 | — | — | WO | disclosed |
| US-20250186441-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | OXALURX, INC. | 2025-06-12 | — | — | US | disclosed |
| WO-2025106644-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ALPHA-V BETA-1 INTEGRIN | MORPHIC THERAPEUTIC, INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| CN-118302418-B | Aromatic heterocyclic compound and application thereof | 中国科学院上海药物研究所 | 2025-05-02 | — | — | CN | disclosed |
| US-20250066357-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2025-02-27 | — | — | US | disclosed |
| US-20250042862-A1 | AROMATIC HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2025-02-06 | — | — | US | disclosed |
| US-12213976-B2 | Compounds and methods for treating oxalate-related diseases | OXALURX, INC. (US) | 2025-02-04 | — | — | US | disclosed |
| US-12187721-B2 | Protein tyrosine phosphatase inhibitors | ARRAY BIOPHARMA INC. (US) | 2025-01-07 | — | — | US | disclosed |
| EP-4217062-B1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-10-09 | — | — | EP | disclosed |
| US-12110291-B2 | Glutarimide-containing pan-KRAS-mutant degrader compounds and uses thereof | TIGER BIOTHERAPEUTICS INC. (US) | 2024-10-08 | — | — | US | disclosed |
| EP-1569911-B1 | INDAZOLE DERIVATIVES AS CRF ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2008-07-02 | — | — | EP | disclosed |
| EP-1569911-B1 | INDAZOLE DERIVATIVES AS CRF ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2008-07-02 | — | — | EP | disclosed |
| US-20070213373-A1 | Indazole derivatives as CRF antagonists | COURNOYER RICHARD L | 2007-09-13 | — | — | US | disclosed |
| US-7214699-B2 | Indazole derivatives as CRF antagonists | ROCHE PALO ALTO LLC (US) | 2007-05-08 | — | — | US | disclosed |
| US-7214699-B2 | Indazole derivatives as CRF antagonists | ROCHE PALO ALTO LLC (US) | 2007-05-08 | — | — | US | disclosed |
| US-7214699-B2 | Indazole derivatives as CRF antagonists | ROCHE PALO ALTO LLC (US) | 2007-05-08 | — | — | US | disclosed |
| CN-1732158-A | indazole derivatives as corticotropin releasing factor antagonists | HOFFMANN LA ROCHE (CH) | 2006-02-08 | — | — | CN | disclosed |
| EP-1569911-A1 | INDAZOLE DERIVATIVES AS CRF ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004050634-A1 | INDAZOLE DERIVATIVES AS CRF ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-17 | — | — | WO | disclosed |
| US-20040110815-A1 | Indazole derivatives as CRF antagonists | ROCHE PALO ALTO LLC | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066357-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | PPM1A, PPM1F, PPP5C | NOS1 2104/4885ALDH1A1 1850/4885GLA 1252/4885 |
| US-12187721-B2 | Protein tyrosine phosphatase inhibitors | PPM1A, PTP4A1, PPP5C | NOS1 2327/4885ALDH1A1 1775/4885GLA 1088/4885 |
| US-20070213373-A1 | Indazole derivatives as CRF antagonists | CRHR1, CRHR2, CRH | NOS1 1456/4885ALDH1A1 1289/4885GLA 4873/4885 |
| US-20040110815-A1 | Indazole derivatives as CRF antagonists | CRHR1, CRHR2, ARRB1 | NOS1 1868/4885ALDH1A1 1266/4885GLA 4852/4885 |
| US-20250042862-A1 | AROMATIC HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | KDM1B, KDM1A, KDM3B | NOS1 651/4885ALDH1A1 165/4885GLA 1999/4885 |
| US-12110291-B2 | Glutarimide-containing pan-KRAS-mutant degrader compounds and uses thereof | KRAS, VHL, HRAS | NOS1 4465/4885ALDH1A1 1826/4885GLA 194/4885 |
| US-20250186441-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | XDH, PNPO, OAT | NOS1 1153/4885ALDH1A1 543/4885GLA 9/4885 |
| US-12213976-B2 | Compounds and methods for treating oxalate-related diseases | XDH, PNPO, OAT | NOS1 1153/4885ALDH1A1 543/4885GLA 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.